<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10678340
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     02
    </month>
    <day>
     24
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     02
    </month>
    <day>
     24
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     14
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0094-3509
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       49
      </volume>
      <issue>
       1
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        Jan
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of family practice
     </title>
     <isoabbreviation>
      J Fam Pract
     </isoabbreviation>
    </journal>
    <articletitle>
     The evidence regarding the drugs used for ventricular rate control.
    </articletitle>
    <pagination>
     <medlinepgn>
      47-59
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      Our goal was to determine what drugs are most efficacious for controlling the ventricular rate in patients with atrial fibrillation.
     </abstracttext>
     <abstracttext label="SEARCH STRATEGY" nlmcategory="METHODS">
      We conducted a systematic review of the literature published before May 1998, beginning with searches of The Cochrane Collaboration's CENTRAL database and MEDLINE.
     </abstracttext>
     <abstracttext label="SELECTION CRITERIA" nlmcategory="METHODS">
      We included English-language articles describing randomized controlled trials of drugs used for heart rate control in adults with atrial fibrillation. DATA COLLECTION/ANALYSIS: Abstracts of trials were reviewed independently by 2 members of the study team. We reviewed English-language abstracts of non-English-language publications to assess qualitative consistency with our results.
     </abstracttext>
     <abstracttext label="MAIN RESULTS" nlmcategory="RESULTS">
      Forty-five articles evaluating 17 drugs met our criteria for review. In the 5 trials of verapamil and 5 of diltiazem, heart rate was reduced significantly (P &lt;.05), both at rest and with exercise, compared with placebo, with equivalent or improved exercise tolerance in 6 of 7 comparisons. In 7 of 12 comparisons of a beta-blocker with placebo, the beta-blocker was efficacious for control of resting heart rate, with evidence that the effect is drug specific, as nadolol and atenolol proved to be most efficacious. All 9 comparisons demonstrated good heart rate control with beta-blockers during exercise, although exercise tolerance was compromised in 3 of 9 comparisons. In 7 of 8 trials, digoxin administered alone slowed the resting heart rate more than placebo, but it did not significantly slow the rate during exercise in 4 studies. The trials evaluating other drugs yielded insufficient evidence to support their use, but those drugs may yet be promising.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The calcium-channel blockers verapamil or diltiazem, or select beta-blockers are efficacious for heart rate control at rest and during exercise for patients with atrial fibrillation without a clinically important decrease in exercise tolerance. Digoxin is useful when rate control during exercise is less a concern.
     </abstracttext>
    </abstract>
    <affiliation>
     The Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Segal
      </lastname>
      <forename>
       J B
      </forename>
      <initials>
       JB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       McNamara
      </lastname>
      <forename>
       R L
      </forename>
      <initials>
       RL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Miller
      </lastname>
      <forename>
       M R
      </forename>
      <initials>
       MR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kim
      </lastname>
      <forename>
       N
      </forename>
      <initials>
       N
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Goodman
      </lastname>
      <forename>
       S N
      </forename>
      <initials>
       SN
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Powe
      </lastname>
      <forename>
       N R
      </forename>
      <initials>
       NR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Robinson
      </lastname>
      <forename>
       K
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Yu
      </lastname>
      <forename>
       D
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bass
      </lastname>
      <forename>
       E B
      </forename>
      <initials>
       EB
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <grantlist completeyn="Y">
     <grant>
      <grantid>
       290-97-006
      </grantid>
      <agency>
       PHS HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Fam Pract
    </medlineta>
    <nlmuniqueid>
     7502590
    </nlmuniqueid>
    <issnlinking>
     0094-3509
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Adrenergic beta-Antagonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Arrhythmia Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Calcium Channel Blockers
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      20830-75-5
     </registrynumber>
     <nameofsubstance>
      Digoxin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      42399-41-7
     </registrynumber>
     <nameofsubstance>
      Diltiazem
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      52-53-9
     </registrynumber>
     <nameofsubstance>
      Verapamil
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adrenergic beta-Antagonists
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Arrhythmia Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Atrial Fibrillation
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bias (Epidemiology)
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Calcium Channel Blockers
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Digoxin
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diltiazem
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Evidence-Based Medicine
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Exercise
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heart Rate
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Research Design
     </descriptorname>
     <qualifiername majortopicyn="Y">
      standards
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Rest
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ventricular Function
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Verapamil
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    67
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      2
     </month>
     <day>
      26
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      2
     </month>
     <day>
      26
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      2
     </month>
     <day>
      26
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10678340
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

